Susanne Baumeister

Real World Outcomes for Young Adult Patients Receiving CD19 CAR T-cell Therapy. Blood Adv. 2025 Mar 24. View Real World Outcomes for Young Adult Patients Receiving CD19 CAR T-cell Therapy. Abstract

B-cell-directed CAR T-cell therapy activates CD8+ cytotoxic CARneg bystander T cells in patients and nonhuman primates. Blood. 2024 07 04; 144(1):46-60. View B-cell-directed CAR T-cell therapy activates CD8+ cytotoxic CARneg bystander T cells in patients and nonhuman primates. Abstract

Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation. Clin Case Rep. 2023 Nov; 11(11):e8190. View Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation. Abstract

Mediport use as an acceptable standard for CAR T cell infusion. Front Immunol. 2023; 14:1239132. View Mediport use as an acceptable standard for CAR T cell infusion. Abstract

Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. EClinicalMedicine. 2023 Nov; 65:102268. View Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. Abstract

Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Blood Adv. 2023 08 22; 7(16):4647-4657. View Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Abstract

HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL. Blood Adv. 2023 06 27; 7(12):2758-2771. View HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL. Abstract

Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Blood Adv. 2023 May 24. View Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Abstract

Getting (T cells) ENGaged. Haematologica. 2023 04 01; 108(4):951-953. View Getting (T cells) ENGaged. Abstract

Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2023 01 10; 41(2):354-363. View Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia. Abstract

Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation. Front Oncol. 2022; 12:841117. View Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation. Abstract

Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. Front Immunol. 2020; 11:580328. View Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. Abstract

Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation. Front Immunol. 2020; 11:191. View Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation. Abstract

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunol Res. 2019 01; 7(1):100-112. View Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Abstract

Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy. Cytotherapy. 2018 07; 20(7):952-963. View Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy. Abstract

Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice. J Immunol. 2016 12 15; 197(12):4674-4685. View Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice. Abstract

Coinhibitory Pathways in Immunotherapy for Cancer. Annu Rev Immunol. 2016 05 20; 34:539-73. View Coinhibitory Pathways in Immunotherapy for Cancer. Abstract

Contribution of CD8+ T cells to containment of viral replication and emergence of mutations in Mamu-A*01-restricted epitopes in Simian immunodeficiency virus-infected rhesus monkeys. J Virol. 2008 Jun; 82(11):5631-5. View Contribution of CD8+ T cells to containment of viral replication and emergence of mutations in Mamu-A*01-restricted epitopes in Simian immunodeficiency virus-infected rhesus monkeys. Abstract

Increased loss of CCR5+ CD45RA- CD4+ T cells in CD8+ lymphocyte-depleted Simian immunodeficiency virus-infected rhesus monkeys. J Virol. 2008 Jun; 82(11):5618-30. View Increased loss of CCR5+ CD45RA- CD4+ T cells in CD8+ lymphocyte-depleted Simian immunodeficiency virus-infected rhesus monkeys. Abstract

G-CSF mobilizes slanDCs (6-sulfo LacNAc+ dendritic cells) with a high proinflammatory capacity. Blood. 2007 Oct 15; 110(8):3078-81. View G-CSF mobilizes slanDCs (6-sulfo LacNAc+ dendritic cells) with a high proinflammatory capacity. Abstract

Immunodomination in the evolution of dominant epitope-specific CD8+ T lymphocyte responses in simian immunodeficiency virus-infected rhesus monkeys. J Immunol. 2006 Jan 01; 176(1):319-28. View Immunodomination in the evolution of dominant epitope-specific CD8+ T lymphocyte responses in simian immunodeficiency virus-infected rhesus monkeys. Abstract